Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 10, 2007, Pages 3949-3957

  Hassan, Memy H ^a,b   Salama, Salama A ^a,b   Arafa, Hossam M M ^b   Hamada, Farid M A ^b   Al Hendy, Ayman ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Al Azhar University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DOMINANT NEGATIVE ESTROGEN RECEPTOR GENE; ESTROGEN METABOLISM; ESTROGEN RESPONSIVE ELEMENT; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; NONHUMAN; PRIORITY JOURNAL; RAT; UTERUS MYOMA; WESTERN BLOTTING;

ADENOVIRIDAE;

EID: 35348950974     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0823     Document Type: Article

References (80)

1. Chen W, Yoshida S, Ohara N, Matsuo H, Morizane M, Maruo T 2005 Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and upregulates apoptosis in association with enhanced poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells. J Clin Endocrinol Metab 90:884-892
2. Benassayag C, Leroy MJ, Rigourd V, Robert B, Honore JC, Mignot TM, Vacher-Lavenu MC, Chapron C, Ferre F 1999 Estrogen receptors (ERα/ERβ) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol 276:E1112-E1118
3. Wang H, Wu X, Englund K, Masironi B, Eriksson H, Sahlin L 2001 Different expression of estrogen receptors α and β in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment. Gynecol Endocrinol 15:443-452
4. Brandon DD, Erickson TE, Keenan EJ, Strawn EY, Novy MJ, Burry KA, Warner C, Clinton GM 1995 Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 80:1876-1881
5. Matsuo H, Maruo T, Samoto T 1997 Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82:293-299
6. Al-Hendy A, Salama SA 2006 Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig 13:136-144
7. Sabbah M, Courilleau D, Mester J, Redeuilh G 1999 Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA 96:11217-11222
8. Kovacs KA, Oszter A, Gocze PM, Kornyei JL, Szabo I 2001 Comparative analysis of cyclin D1 and oestrogen receptor (α and β) levels in human leiomyoma and adjacent myometrium. Mol Hum Reprod 7:1085-1091
9. Hyder SM, Huang JC, Nawaz Z, Boettger-Tong H, Makela C, Chiappetta C, Stancel GM 2000 Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 108(Suppl 5):785-790
10. Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, Perrett CW 2001 Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 101:691-695
11. Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruck-Ware R, Johnnson ED, Maruo T 2006 Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 21:2408-2416
12. Shimomura Y, Matsuo H, Samoto T, Maruo T 1998 Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83:2192-2198
13. Kurachi O, Matsuo H, Samoto T, Maruo T 2001 Tumor necrosis factor-α expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab 86:2275-2280
14. Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, Erickson TE, Warner C, Keenan EJ, Clinton GM 1993 Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169:78-85
15. Viville B, Charnock-Jones DS, Sharkey AM, Wetzka B, Smith SK 1997 Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 12:815-822
16. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J 1999 Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 14:2844-2850
17. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johannson ED, Maruo T 2005 Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 90:953-961
18. Wang J, Ohara N, Wang Z, Chen W, Morkikawa A, Sasaki H, DeManno DA, Chwalisz K, Maruo T 2006 A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFβ3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 21:1869-1877
19. Petz LN, Ziegler YS, Loven MA, Nardulli AM 2002 Estrogen receptor α and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 143:4583-4591
20. Petz LN, Nardulli AM 2000 Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 14:972-985
21. Liu J, Li J, Sidell N 2007 Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells. Cancer Chemother Pharmacol 59:217-225
22. Lazennec G, Alcorn JL, Katzenellenbogen BS 1999 Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol Endocrinol 13:969-980
23. Al-Hendy A, Lee EJ, Wang HQ, Copland JA 2004 Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 191:1621-1631
24. Lee EJ, Duan WR, Jakacka M, Gehm BD, Jameson JL 2001 Dominant negative ER induces apoptosis in GH4 pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinology 142:3756-3763
25. Al-Hendy A, Magliocco AM, Al Tweigeri T, Braileanu G, Crellin N, Li H, Curiel D, Chedrese PJ 2000 Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol 182:553-559
26. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C 1995 Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 146:1568-1579
27. Rauk PN, Surti U, Roberts JM, Michalopoulos G 1995 Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol 173:571-577
28. Carney SA, Tahara H, Swartz CD, Risinger JI, He H, Moore AB, Haseman JK, Barrett JC, Dixon D 2002 Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest 82:719-728
29. Al Hendy A, Salama S 2006 Gene therapy and uterine leiomyoma: a review. Hum Reprod Update 16:385-400
30. Salama S, Kamel M, Christman G, Wang H, Al-Hendy A 2006 Gene therapy of uterine fibroids: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells. Gynecol Obstet Invest 63:61-70
31. Reed JC, Jurgensmeier JM, Matsuyama1998 Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1366:127-137
32. Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC, Robboy SJ 2002 Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch 441:53-62
33. Sullivan PJ, Campagnoli RP, Latimer KS, Evaluation of proliferation marker (PCNA, Ki-67, and p53) expression in avian hepatic tissues. Proc International Virtual Conferences in Veterinary Medicine, Athens, GA, 1998 (Abstract 31)
34. Geerts WH, Pineo GF, Heit JA, Berggvist D, Lassen MR, Colwell CW, Ray JG 2004 Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S-400S
35. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G 1993 Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7:812-821
36. Gilroy DW, Saunders MA, Wu KK 2001 COX-2 expression and cell cycle progression in human fibroblasts. Am J Physiol Cell Physiol 281:C188-C194
37. Murphy LJ, Ghahary A 1990 Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 11:443-453
38. Enmark E, Gustafsson JA 1999 Oestrogen receptors: an overview. J Intern Med 246:133-138
39. Tsai MJ, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
40. Loy CJ, Evelyn S, Lim FK, Liu MH, Yong EL 2005 Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-γ ligand, pioglitazone. Mol Hum Reprod 11:561-566
41. Raff MC 1992 Social controls on cell survival and cell death. Nature 356:397-400
42. Kyprianou N, English HF, Davidson NE, Isaacs JT 1991 Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162-166
43. Teixeira C, Reed JC, Pratt MA 1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907
44. Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ 1999 Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med 44:487-492
45. Wu X, Blanck A, Olovsson M, Henriksen R, Lindblom B 2002 Expression of Bcl-2, Bcl-x, Mcl-1, Bax and Bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. J Steroid Biochem Mol Biol 80:77-83
46. Wang TT, Phang JM 1995 Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55:2487-2489
47. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhidal C, Sate S 1999 Mechanisms of transcriptional activation of bcl-2 gene expression by 17β-estradiol in breast cancer cells. J Biol Chem 274:32099-32107
48. El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV 1998 Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 51:149-168
49. El Etreby MF, Liang Y, Lewis RW, Schoenlein PV 2000 Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 43:31-42
50. Perillo B, Sasso A, Abbondanza C, Palumbo G 2000 17β-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20:2890-2901
51. Reed JC 1998 Bcl-2 family proteins. Oncogene 17:3225-3236
52. Nomura M, Shimizu S, Ito T, Narita M, Matsuda H, Tsujimoto Y 1999 Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2. Cancer Res 59:5542-5548
53. Butt AJ, Firth SM, King MA, Baxter RC 2000 Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275:39174-39181
54. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM 1986 Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 166:209-219
55. Nichols AF, Sancar A 1992 Purification of PCNA as a nucleotide excision repair protein. Nucleic Acids Res 20:2441-2446
56. Shivji KK, Kenny MK, Wood RD 1992 Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69:367-374
57. Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, Aisen PS, Pasinetti GM 2002 Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 23:327-334
58. Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, Yun YS, Pyo H 2005 Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65:9501-9509
59. Doherty GA, Byrne SM, Molloy ES, Cox CM, Griffin NM, Austin SC, Kay EW, Murray FE, Fitzgerald DJ 2005 Regulation of cell cycle progression by cyclooxygenase-2 in colorectal cancer; the role of the EP4 receptor, a novel therapeutic target. Endoscopy 37(12):922893 (Abstract 31)
60. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL 1997 Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272:10882-10894
61. Challis JG, Lye SJ 1994 Parturition. In: Knobil E, Neill JD, eds. The physiology of reproduction. New York: Raven Press; 985-1031
62. Espey LL 1994 Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 50:233-238
63. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM 1996 Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809
64. Hla T, Ristimaki A, Appleby S, Barriocanal JG 1993 Cyclooxygenase gene expression in inflammation and angiogenesis. Ann NY Acad Sci 696:197-204
65. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC 1999 Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31:551-557
66. Munroe DG, Wang EY, MacIntyre JP, Tam SS, Lee DH, Taylor GR, Zhou L, Plante RK, Kazmi SM, Bauerle PA 1995 Novel intracellular signaling function of prostaglandin H synthase-1 in NF-κB activation. J Inflamm 45:260-268
67. Folkman J, Klagsbrun M 1987 Angiogenic factors. Science 235:442-447
68. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK 1995 Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 80:1853-1858
69. Dixon D, He H, Haseman JK 2000 Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 108:7-8
70. Hofmann GE, Rao CV, Barrows GH, Schultz GS, Sanfilippo JS 1984 Binding sites for epidermal growth factor in human uterine tissues and leiomyomas. J Clin Endocrinol Metab 58:880-884
71. Nelson KG, Takahashi T, Bossert NL, Walmer DK, McLachlan JA 1991 Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci USA 88:21-25
72. Yeh J, Rein M, Nowak R 1991 Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata. Fertil Steril 56:997-1000
73. Rossi MJ, Chegini N, Masterson BJ 1992 Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 130:1716-1727
74. Lumsden MA, West CP, Bramley T, Rumgay L, Baird DT 1988 The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynaecol 95:1299-1304
75. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T 1989 Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160:637-641
76. Tiltman AJ 1985 The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4:89-96
77. Creveling CR 2003 The role of catechol-O-methyltransferase in the inactivation of catecholestrogen. Cell Mol Neurobiol 23:289-291
78. Salama SA, Ho SL, Wang HQ, Tenhunen J, Tilgmann C, Al Hendy A 2006 Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. Fertil Steril 86:259-262
79. Palmer SS, Haynes-Johnson D, Diehl T, Nowak RA 1998 Increased expression of stromelysin 3 mRNA in leiomyomas (uterine fibroids) compared with myometrium. J Soc Gynecol Investig 5:203-209
80. Lee YJ, Lee EB, Kwon YE, Lee JJ, Cho WS, Kim HA, Song YW 2003 Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproternase-1 in osteoarthritis chondrocytes. Rheumatol Int 23:282-288